Author:
Zhao Jun,Zheng Hui,Wang Xin,Wang Xuefei,Shi Yunzhou,Xie Chaorong,Tao Qingfeng,Li Da,Sun Jingwen,Tian Junjian,Gao Junxia,Liu Huimin,Shi Suhua,Ni Jinxia,Xue Rongdan,Hu Hui,Chen Min,Yu Shuguang,Li Zhigang
Abstract
AbstractPrevious studies have confirmed that acupuncture for irritable bowel syndrome (IBS) provided an additional benefit over usual care alone. Therefore, we performed a multicenter, randomized, sham-controlled trial to assess the efficacy and safety of acupuncture versus sham acupuncture for refractory IBS in patients in the context of conventional treatments. Patients in the acupuncture and sham acupuncture groups received real or sham acupuncture treatment in 3 sessions per week for a total of 12 sessions. The primary outcome was a change in the IBS–Symptom Severity Scale (IBS-SSS) score from baseline to week 4. A total of 521 participants were screened, and 170 patients (85 patients per group) were enrolled and included in the intention-to-treat analysis. Baseline characteristics were comparable across the two groups. From baseline to 4 weeks, the IBS-SSS total score decreased by 140.0 (95% CI: 126.0 to 153.9) in the acupuncture group and 64.4 (95% CI: 50.4 to 78.3) in the sham acupuncture group. The between-group difference was 75.6 (95% CI: 55.8 to 95.4). Acupuncture efficacy was maintained during the 4-week follow-up period. There were no serious adverse events. In conclusion, acupuncture provided benefits when combined with treatment as usual, providing more options for the treatment of refractory IBS.
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Quigley EM, Fried M, Gwee KA, Khalif I, Hungin AP, Lindberg G, Abbas Z, Fernandez LB, Bhatia SJ, Schmulson M, Olano C, LeMair A. Review Team. World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome: a global perspective update September 2015. J Clin Gastroenterol 2016; 50(9): 704–713
2. Study group of functional gastrointestinal disorders, study group of gastrointestinal motility, Chinese society of gastroenterology, Chinese medical association. Chinese expert consensus of irritable bowel syndrome in 2020. Chin J Dig 2020; 40(12): 803–818 (in Chinese)
3. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10(7): 712–721.e4
4. Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley EM, Rajilić-Stojanović M, Schemann M, Schwille-Kiuntke J, Simren M, Zipfel S, Spiller RC. Irritable bowel syndrome. Nat Rev Dis Primers 2016; 2(1): 16014
5. Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 2020; 17(8): 473–486